Pertuzumab clinical trials
Also written Perjeta, RO4368451 and rhuMAb 2C4.
Related medicines add 1 study
Counted the way a researcher would: Pertuzumab with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
ClinicalTrials.gov finds 448 studies for pertuzumab. How that becomes 156 here
Every study that search finds has been read, apart from the 1 newest, to see whether and how it gives pertuzumab. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count
- 448Found by its intervention search · See all 448 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 347 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −20
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- Vaccine Therapy in Treating Patients With Metastatic Solid TumorsNCT01376505 · Named only as a model for the vaccine's designReport a problem
- MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer PatientsNCT02213744 · Earlier treatment, not given in this studyReport a problem
- The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast CancerNCT03414658 · Earlier treatment, not given in this studyReport a problem
- Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced CardiotoxicityNCT03964142 · Not named; HER2 therapy in general during cardiac rehabilitationReport a problem
- Pyrotinib in Breast Cancer Patients With Poor Response to the Neoadjuvant Treatment of Trastuzumab and PertuzumabNCT04255056 · Earlier treatment, not given in this studyReport a problem
- T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast CancerNCT04351230 · Earlier treatment, not given in this studyReport a problem
- A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)NCT04740918 · Earlier treatment, not given in this studyReport a problem
- Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer PatientsNCT04983121 · Earlier treatment, not given in this studyReport a problem
- Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast CancerNCT05255523 · Given before entry; pyrotinib followsReport a problem
- Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+PertuzumabNCT05744375 · Earlier treatment, not given in this studyReport a problem
- Pyrotinib in Women With High-risk in Early Stage Breast CancerNCT05834764 · Earlier treatment, not given in this studyReport a problem
- HER-2 B Cell Peptide VaccineNCT06414733 · Not given; the vaccine is modelled on itReport a problem
- Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABCNCT06754059 · Given before entry; pyrotinib maintenance followsReport a problem
- Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted TherapyNCT06828588 · Not named; HER2 therapy in general during PET imagingReport a problem
- HER2 Vaccine for Locally Advanced Breast CancerNCT06949410 · Not given; the vaccine is modelled on itReport a problem
- A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast CancerNCT07150767 · Not given; BioTTT001 is studiedReport a problem
- GIM27-THERapy: a Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER-2 Positive Breast Cancer Patients in Real World SettingNCT07583485 · Earlier treatment, not given in this studyReport a problem
- Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast CancerNCT07600164 · Given before entry in one cohortReport a problem
- Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast CancerNCT07616453 · Named only in the record's official titleReport a problem
- Pyrotinib for HER2-Positive Advanced Breast Cancer Previously Treated With Trastuzumab and PertuzumabNCT07810634 · Earlier treatment, not given in this studyReport a problem
- 428Give pertuzumab to participants
- −44Observe patients on it, or give it outside a trial
- −4Use it as a tool: an imaging tracer or a test of drug response
- −33Compare another treatment with it
- −191Give it beside what is tested
- 156Test it: the count on this site
Get an email when these change. Save the pertuzumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 8 Jun 2012 · PERJETA · BLA 125409 (FDA, Drugs@FDA)
- European Union
- 4 Mar 2013 · Perjeta · EMEA/H/C/002547 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
155 studies that test it; most in 2021 (13); 1 more planned to start later
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2003 | 5 |
| 2004 | 2 |
| 2005 | 4 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 4 |
| 2010 | 5 |
| 2011 | 4 |
| 2012 | 5 |
| 2013 | 8 |
| 2014 | 10 |
| 2015 | 11 |
| 2016 | 9 |
| 2017 | 5 |
| 2018 | 7 |
| 2019 | 1 |
| 2020 | 10 |
| 2021 | 13 |
| 2022 | 12 |
| 2023 | 10 |
| 2024 | 7 |
| 2025 | 9 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 57 · Other 99
Hoffmann-La Roche (32) · Genentech, Inc. (11) · Dana-Farber Cancer Institute (7) · National Cancer Institute (NCI) (4) · MedSIR (3) · The Netherlands Cancer Institute (3) · City of Hope Medical Center (2) · H. Lee Moffitt Cancer Center and Research Institute (2)
Often tested with
Tested in the same studies.
Trastuzumab (89) · Ado-Trastuzumab Emtansine (15) · Paclitaxel (15) · Atezolizumab (14) · Pertuzumab/Trastuzumab/Hyaluronidase-zzxf (10) · Olaparib (10) · Cobimetinib (10) · Docetaxel (9)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 11 phase 3 studies under way
Pertuzumab is the comparator. A study of two new drugs counts under both.
- 4Docetaxel · Shanghai JMT-Bio Inc., R-Pharm · next primary completion Dec 2026
- 2Anbenitamab · Shanghai JMT-Bio Inc. · next primary completion Dec 2026
- 2Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · next primary completion Sep 2027
- 1Trastuzumab rezetecan · Jiangsu HengRui Medicine Co., Ltd. · next primary completion Dec 2027
- 1ARX788 · Caigang Liu
- 1Ado-Trastuzumab Emtansine · Thomas Hatschek
- 1Trastuzumab deruxtecan · Prof. Wolfgang Janni · next primary completion Apr 2032
- 1Disitamab vedotin · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · next primary completion Jun 2031
New treatments tested with it · 8 most studied
New when their studies opened, with pertuzumab beside them; studies of each.
Reaching primary completion within a year · 17, 5 in phase 3
Studies that test pertuzumab, phase 3 first.
- Dec 2026Identification and Treatment Of Micrometastatic Disease in Stage III Colon CancerPhase 3 · Massachusetts General Hospital
- Mar 2027A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical TrialPhase 3 · Hoffmann-La Roche
- May 2027Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)Phase 3 · AstraZeneca
- Jul 2027TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal CancerPhase 3 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Oct 2027Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or CarcinosarcomaPhase 3 · National Cancer Institute (NCI)
- Dec 2026Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast CancerPhase 2 · Shanghai Jiao Tong University School of Medicine
- Dec 2026Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal CancerPhase 2 · Peking Union Medical College Hospital
- Dec 2026Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast CancerNot applicable · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Dec 2026Identification of HER2-Positive Breast Cancer Molecular Characterization and SubtypesNot applicable · Shandong Cancer Hospital and Institute
- Mar 2027Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast CancerPhase 2 · MedSIR
Studies
Open first, then newest update. How each study uses pertuzumab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 156
- Neoadjuvant Trastuzumab, Pertuzumab and Zongertinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-5 StudyNot yet recruitingPhase 1The Netherlands Cancer InstituteNCT07928479With trastuzumab and zongertinib, without chemotherapy, before surgeryReport a problem
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingPhase 2Helsinki University Central HospitalNCT05159245One approved drug pair matched to tumour profileWritten as Trastuzumab+PertuzumabReport a problem
- Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR TrialRecruitingPhase 2M.D. Anderson Cancer CenterNCT07407920Reduced adjuvant therapy after a molecular complete responseWritten as PertuzumabReport a problem
- ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT06876714Six against 12 months after a complete responseWritten as PertuzumabReport a problem
- HER2-positive Breast Cancer Without Intravenous Neoadjuvant TherapyNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07848633Under the skin with trastuzumab and oral paclitaxel before surgeryReport a problem
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingPhase 2American Society of Clinical OncologyNCT02693535One approved drug pair matched to tumour geneticsWritten as Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT)Report a problem
- Molecularly Tailored Therapy in Advanced Pancreatic CancerNot yet recruitingPhase 2Herlev HospitalNCT07802418One matched option in tailored pancreatic cancer therapyReport a problem
- BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast CancerRecruitingPhase 2University of Illinois at ChicagoNCT06441890With trastuzumab and a taxane, guided by MammaPrintWritten as PertuzumabReport a problem
- The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerRecruitingPhase 2Dana-Farber Cancer InstituteNCT06439693With trastuzumab and a taxane, then T-DXd, in a curative sequenceWritten as PertuzumabReport a problem
- Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.RecruitingPhase 2UNICANCERNCT06450314Stopping HER2 maintenance after a negative ctDNA testReport a problem
- Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast CancerRecruitingPhase 4Wen-Ming CaoNCT07695259With trastuzumab and olaparib before surgery in older womenWritten as olaparib combined with trastuzumab and pertuzumabReport a problem
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolRecruitingPhase 2/3Cancer Research UKNCT05722886With trastuzumab in rare HER2 cancersWritten as Trastuzumab in combination with pertuzumabReport a problem
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499One option in a precision neoadjuvant platformWritten as PertuzumabReport a problem
- Neoadjuvant Trastuzumab, Pertuzumab Plus Metronomic Vinorelbine for Elderly HER2-Positive Breast CancerNot yet recruitingNot applicableTianjin Medical University Cancer Institute and HospitalNCT07589972With trastuzumab and metronomic vinorelbine in elderly patientsReport a problem
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379With trastuzumab emtansine in one I-SPY armWritten as T-DM1 and PertuzumabReport a problem
- Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial)Not yet recruitingPhase 2National Taiwan University HospitalNCT07565324With trastuzumab and Lipo-Dox, guided by ultrasound and ctDNAWritten as PertuzumabReport a problem
- Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast CancerRecruitingNot applicableSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07095023With trastuzumab under the skin and oral paclitaxel before surgeryWritten as Paclitaxel oral solution plus Subcutaneous Pertuzumab/TrastuzumabReport a problem
- Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.Enrolling by invitationPhase 2Zhejiang Provincial People's HospitalNCT07550972With lenvatinib before head and neck surgeryReport a problem
- Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast CancerRecruitingPhase 2Rutgers, The State University of New JerseyNCT07402473With trastuzumab and chemotherapy, adapted by biomarkerWritten as PertuzumabReport a problem
- Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After SurgeryRecruitingPhase 2University of ChicagoNCT06348134With docetaxel in Nigerian womenWritten as Pertuzumab InjectionReport a problem
See all 156 studies that test pertuzumab →
Behind its US label · 5 — the studies the FDA label of PERJETA describes
From the Clinical Studies section of PERJETA (2026-04), as openFDA has it. A study the site does not hold is left out.
- A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.CompletedPhase 2Hoffmann-La RocheNCT00545688Report a problem
- A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast CancerCompletedPhase 3Genentech, Inc.NCT00567190Report a problem
- A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast CancerCompletedPhase 2Hoffmann-La RocheNCT00976989Report a problem
- A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast CancerCompletedPhase 3Hoffmann-La RocheNCT01358877Report a problem
- A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast CancerCompletedPhase 2Hoffmann-La RocheNCT02132949Report a problem
Tested on its own · 19 — no other medicine in its arm
- Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + DocetaxelActive, not recruitingPhase 3BioRay Pharmaceutical Co., Ltd.NCT04514419Biosimilar HS627 against Perjeta with trastuzumab and docetaxelWritten as HS627Report a problem
- Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.WithdrawnPhase 3EirGenix, Inc.NCT06884254Biosimilar EG1206A against Perjeta before surgeryWritten as EG1206AReport a problem
- Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast CancerActive, not recruitingPhase 3BiocadNCT05802225Biosimilar BCD-178 against Perjeta before surgeryWritten as BCD-178Report a problem
- A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast CancerActive, not recruitingPhase 3Shanghai Henlius BiotechNCT05346224Biosimilar HLX11 against Perjeta before surgeryWritten as HLX11Report a problem
- Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast CancerActive, not recruitingPhase 3Helsinki University Central HospitalNCT02625441Shorter course with trastuzumab against standard trastuzumabWritten as PertuzumabReport a problem
- Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta® in Healthy ManActive, not recruitingPhase 1Mabscale, LLCNCT05825781Biosimilar against Perjeta in healthy menWritten as PertuzumabReport a problem
- A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)CompletedPhase 3Zydus Lifesciences LimitedNCT05283837Biosimilar ZRC-3277 against PerjetaWritten as Pertuzumab (ZRC-3277)Report a problem
- A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy VolunteersStatus unknownPhase 1BiocadNCT05738993Biosimilar BCD-178 against Perjeta in healthy volunteersWritten as BCD-178Report a problem
- A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab) in Healthy Male VolunteersCompletedPhase 1EirGenix, Inc.NCT05471648Biosimilar EG1206A against Perjeta in healthy volunteersWritten as 420 mg EG1206A EirGenix Pertuzumab in 14 mL InjectionReport a problem
- Compare Pharmacokinetics, Safety, and Immunogenicity of HLX11 vs. Perjeta in Healthy Chinese Male SubjectsCompletedPhase 1Shanghai Henlius BiotechNCT04411550Biosimilar HLX11 against Perjeta in healthy volunteersWritten as HLX11Report a problem
- Pharmacokinetic Study of Recombinant Monoclonal Antibody Against Human Epidermal Growth Factor Receptor InjectionCompletedPhase 1The Affiliated Hospital of Qingdao UniversityNCT04820439Biosimilar against Perjeta, drug levelsWritten as recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)Report a problem
- A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian CancerCompletedPhase 2Genentech, Inc.NCT00058552Alone in ovarian cancer by HER2 activationWritten as Pertuzumab (rhuMAb 2C4)Report a problem
- A Study of Pertuzumab in Participants With Prostate CancerTerminatedPhase 2Hoffmann-La RocheNCT02480010Two doses in prostate cancerWritten as PertuzumabReport a problem
- A Study of Pertuzumab in Participants With Metastatic Breast CancerCompletedPhase 2Hoffmann-La RocheNCT02491892Two doses in metastatic breast cancerWritten as PertuzumabReport a problem
- Safety Study of rhuMAb 2C4 to Treat Advanced Solid TumorsCompletedPhase 1Genentech, Inc.NCT00027027Its first study, in solid tumoursWritten as rhuMAb 2C4Report a problem
- Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior ChemotherapyCompletedPhase 2Genentech, Inc.NCT00063154Alone in lung cancerWritten as PertuzumabReport a problem
- Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate CancerCompletedPhase 2Genentech, Inc.NCT00058539Alone in prostate cancerWritten as rhuMAb 2C4 (pertuzumab)Report a problem
- A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer StudyCompletedPhase 2Genentech, Inc.NCT00096941Continued for people from earlier phase II studiesWritten as PertuzumabReport a problem
- Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous TrastuzumabCompletedPhase 2National Institutes of Health Clinical Center (CC)NCT00301899Added to trastuzumab after progression in breast cancerWritten as pertuzumabReport a problem
Tested with established drugs · 32 — they are given beside it
- Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast CancerRecruitingPhase 4Wen-Ming CaoNCT07695259With trastuzumab and olaparib before surgery in older womenWritten as olaparib combined with trastuzumab and pertuzumabReport a problem
- Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast CancerRecruitingPhase 3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05720026Biosimilar SYSA1901 against PerjetaWritten as SYSA1901Report a problem
- Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast CancerRecruitingPhase 2AC Camargo Cancer CenterNCT04993014Added to trastuzumab by tumour cell statusWritten as PertuzumabReport a problem
- A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical TrialActive, not recruitingPhase 3Hoffmann-La RocheNCT02320435Continued for people from earlier pertuzumab studiesWritten as PertuzumabReport a problem
- A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast CancerCompletedPhase 3Hoffmann-La RocheNCT01358877On the US labelAdded to trastuzumab and chemotherapy after breast surgeryWritten as PertuzumabReport a problem
- A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast CancerCompletedPhase 3Japan Breast Cancer Research GroupNCT02514681Retreatment added to trastuzumab and chemotherapyWritten as PertuzumabReport a problem
- Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast CancerCompletedPhase 3CinnagenNCT04957212Biosimilar against Perjeta before surgeryWritten as PertuzumabReport a problem
- A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast CancerCompletedPhase 2Hoffmann-La RocheNCT03674112Under the skin against intravenous, on patient preferenceWritten as Pertuzumab IVReport a problem
- Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.Status unknownPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05985187Biosimilar TQB2440 against PerjetaWritten as TQB2440 injection + Trastuzumab + DocetaxelReport a problem
- Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + DocetaxelCompletedPhase 3Hoffmann-La RocheNCT02586025Added to trastuzumab and chemotherapy before surgeryWritten as PertuzumabReport a problem
- Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast CancerTerminatedPhase 2US Oncology ResearchNCT02229149Added to trastuzumab and chemotherapy after earlier treatmentWritten as PertuzumabReport a problem
- A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerCompletedPhase 3Hoffmann-La RocheNCT02896855Added to trastuzumab and docetaxel in breast cancerWritten as PertuzumabReport a problem
- A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric CancerCompletedPhase 3Hoffmann-La RocheNCT01774786Added to trastuzumab and chemotherapy in gastric cancerWritten as PertuzumabReport a problem
- A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast CancerCompletedPhase 2Hoffmann-La RocheNCT01491737Added to trastuzumab and an aromatase inhibitorWritten as PertuzumabReport a problem
- A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast CancerCompletedPhase 3Hoffmann-La RocheNCT01572038With trastuzumab and a taxane first-line, safetyWritten as PertuzumabReport a problem
- Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast CancerCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT01276041With trastuzumab and paclitaxel in breast cancerWritten as pertuzumab in combination with trastuzumab and paclitaxelReport a problem
- A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast CancerCompletedPhase 3Genentech, Inc.NCT00567190On the US labelAdded to trastuzumab and docetaxel in metastatic breast cancerWritten as PertuzumabReport a problem
- A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)CompletedPhase 3Hoffmann-La RocheNCT01026142Added to trastuzumab and capecitabineWritten as PertuzumabReport a problem
- A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric CancerCompletedPhase 2Hoffmann-La RocheNCT01461057With trastuzumab and chemotherapy in gastric cancer, two dosesWritten as PertuzumabReport a problem
- A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)CompletedPhase 1Hoffmann-La RocheNCT02738970Under-the-skin doses found in healthy volunteersWritten as PertuzumabReport a problem
Showing 20 of 32. See all 32 →
Tested in a combination · 104 — another drug in the study is under test too
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingPhase 2Helsinki University Central HospitalNCT05159245One approved drug pair matched to tumour profileWritten as Trastuzumab+PertuzumabReport a problem
- Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR TrialRecruitingPhase 2M.D. Anderson Cancer CenterNCT07407920Reduced adjuvant therapy after a molecular complete responseWritten as PertuzumabReport a problem
- ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT06876714Six against 12 months after a complete responseWritten as PertuzumabReport a problem
- HER2-positive Breast Cancer Without Intravenous Neoadjuvant TherapyNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07848633Under the skin with trastuzumab and oral paclitaxel before surgeryReport a problem
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingPhase 2American Society of Clinical OncologyNCT02693535One approved drug pair matched to tumour geneticsWritten as Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT)Report a problem
- Molecularly Tailored Therapy in Advanced Pancreatic CancerNot yet recruitingPhase 2Herlev HospitalNCT07802418One matched option in tailored pancreatic cancer therapyReport a problem
- BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast CancerRecruitingPhase 2University of Illinois at ChicagoNCT06441890With trastuzumab and a taxane, guided by MammaPrintWritten as PertuzumabReport a problem
- The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerRecruitingPhase 2Dana-Farber Cancer InstituteNCT06439693With trastuzumab and a taxane, then T-DXd, in a curative sequenceWritten as PertuzumabReport a problem
- Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.RecruitingPhase 2UNICANCERNCT06450314Stopping HER2 maintenance after a negative ctDNA testReport a problem
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolRecruitingPhase 2/3Cancer Research UKNCT05722886With trastuzumab in rare HER2 cancersWritten as Trastuzumab in combination with pertuzumabReport a problem
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499One option in a precision neoadjuvant platformWritten as PertuzumabReport a problem
- Neoadjuvant Trastuzumab, Pertuzumab Plus Metronomic Vinorelbine for Elderly HER2-Positive Breast CancerNot yet recruitingNot applicableTianjin Medical University Cancer Institute and HospitalNCT07589972With trastuzumab and metronomic vinorelbine in elderly patientsReport a problem
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379With trastuzumab emtansine in one I-SPY armWritten as T-DM1 and PertuzumabReport a problem
- Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial)Not yet recruitingPhase 2National Taiwan University HospitalNCT07565324With trastuzumab and Lipo-Dox, guided by ultrasound and ctDNAWritten as PertuzumabReport a problem
- Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast CancerRecruitingNot applicableSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07095023With trastuzumab under the skin and oral paclitaxel before surgeryWritten as Paclitaxel oral solution plus Subcutaneous Pertuzumab/TrastuzumabReport a problem
- Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.Enrolling by invitationPhase 2Zhejiang Provincial People's HospitalNCT07550972With lenvatinib before head and neck surgeryReport a problem
- Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast CancerRecruitingPhase 2Rutgers, The State University of New JerseyNCT07402473With trastuzumab and chemotherapy, adapted by biomarkerWritten as PertuzumabReport a problem
- Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After SurgeryRecruitingPhase 2University of ChicagoNCT06348134With docetaxel in Nigerian womenWritten as Pertuzumab InjectionReport a problem
- Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast CancerRecruitingPhase 2Shanghai Jiao Tong University School of MedicineNCT07393425With trastuzumab in response-guided therapy before surgeryWritten as PertuzumabReport a problem
- An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast CancerNot yet recruitingPhase 2Anhui Provincial Cancer HospitalNCT07299890With trastuzumab, palbociclib and exemestane before surgeryWritten as Trastuzumab and Pertuzumab Combination with Palbociclib and ExemestaneReport a problem
Showing 20 of 104. See all 104 →
Beside an established treatment under test · 85 — an approved drug, surgery or radiation is what the study tests
Tested with pertuzumab: Surgery or a procedure 14 · Trastuzumab 8 · Carboplatin 8 · Radiation 7 · Paclitaxel 7 · atezolizumab 7 · trastuzumab deruxtecan 5 · Albumin-Bound Paclitaxel 5
- T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXdRecruitingPhase 3Daiichi SankyoNCT07683754In every armMaintenance in a T-DXd-led sequenceWritten as PertuzumabReport a problem
- Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at DiagnosisRecruitingPhase 3SWOG Cancer Research NetworkNCT07578116Systemic therapy; surgery and radiation are addedWritten as PertuzumabReport a problem
- Metastasis-directed Therapy for Oligometastases of Breast CancerRecruitingPhase 3Tokyo Medical and Dental UniversityNCT06135714Part of systemic therapy; metastasis-directed therapy is addedReport a problem
- Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.Not yet recruitingPhase 2Novartis PharmaceuticalsNCT07679269In every armContinued beside alpelisib in a roll-over studyWritten as PertuzumabReport a problem
- HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term RemissionRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07459673Partner of trastuzumab deruxtecan in one adaptive stepReport a problem
- Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast CancerNot yet recruitingPhase 2Polly A. Niravath, MDNCT07772245In every armBackbone with trastuzumab; retifanlimab is addedWritten as PertuzumabReport a problem
- De-escalation Neoadjuvant Therapy for Intermediate Risk HER2-positive Early BreastNot yet recruitingPhase 3Guangdong Provincial People's HospitalNCT07748260Both arms take it with trastuzumab; 4 against 6 cyclesReport a problem
- Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone MetastasesNot yet recruitingNot applicableWest China HospitalNCT07687225Standard systemic option; primary tumour surgery is testedReport a problem
- Elacestrant in Advanced Triple Positive Breast CancerRecruitingPhase 1/2NYU Langone HealthNCT07612215In every armPartner of elacestrant with trastuzumabWritten as PertuzumabReport a problem
- A Study of Surgery and Radiotherapy in People With Breast CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07053085Standard with trastuzumab; surgery and radiation are addedReport a problem
- Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast CancerRecruitingPhase 2University of Kansas Medical CenterNCT07220135In every armBoth arms take it with docetaxel; carboplatin is omitted in oneWritten as Pertuzumab (or biosimilar)Report a problem
- Effects of Instrument-Assisted Constant-Speed Injection Versus Manual Injection on Pain From Large-Volume Subcutaneous Injection of Pertuzumab and Trastuzumab in Breast Cancer: A Randomized, Self-Controlled StudyNot yet recruitingNot applicableSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07533526Patients take it; the injection method is testedReport a problem
- Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity ManagementRecruitingPhase 2SOLTI Breast Cancer Research GroupNCT07371585In every armPartner of trastuzumab deruxtecan with digital toxicity managementWritten as PertuzumabReport a problem
- A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation ModelNot yet recruitingPhase 3Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07239271Both arms take it with trastuzumab; adaptive chemotherapy is testedReport a problem
- Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus PertuzumabRecruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05760612In the control arm; neratinib replaces itWritten as Trastuzumab and PertuzumabReport a problem
- Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast CancerRecruitingPhase 3Henan Cancer HospitalNCT07057427In every armBoth arms take it with trastuzumab; nab-paclitaxel against TCbWritten as Trastuzumab + PertuzumabReport a problem
- A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast CancerRecruitingPhase 3Henan Cancer HospitalNCT04547907Both arms take it with trastuzumab; nab-paclitaxel against TCbReport a problem
- Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast CancerRecruitingNot applicableCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06197581One HER2 option beside concurrent radiotherapyReport a problem
- Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast CancerRecruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05159193In every armBoth arms take it with trastuzumab; two chemotherapy regimens comparedWritten as pertuzumab (P)Report a problem
- Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)RecruitingPhase 3Guangdong Provincial People's HospitalNCT04858529Both arms take it with trastuzumab; carboplatin is omitted in oneReport a problem
Showing 20 of 85. See all 85 →
Beside a new treatment under test · 83 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with pertuzumab: trastuzumab rezetecan 10 · pyrotinib 7 · Ado-Trastuzumab Emtansine 3 · Anti-HER2 Antibody-drug Conjugate BL-M07D1 3 · culmerciclib 3 · inavolisib 2 · dalpiciclib 2 · HRS-4508 2
- Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06686394Partner of new patritumab deruxtecanWritten as PertuzumabReport a problem
- Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast CancerRecruitingPhase 2Fudan UniversityNCT07581795Both arms take it with trastuzumab; micelles and adebrelimab are comparedReport a problem
- A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast CancerRecruitingPhase 2/3Sichuan Baili Pharmaceutical Co., Ltd.NCT06891833In every armPartner of new BL-M07D1; also in the comparatorWritten as PertuzumabReport a problem
- A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid TumorsRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT06555068One partner of new HRS-6209Written as HRS-6209 in Combination with letrozole and trastuzumab and pertuzumabReport a problem
- Trastuzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast CancerNot yet recruitingPhase 2Hebei Medical University Fourth HospitalNCT07857226In every armPartner of new culmerciclib with fulvestrantWritten as PertuzumabReport a problem
- Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast CancerRecruitingPhase 2GBG Forschungs GmbHNCT05306041Both arms take Phesgo; new inavolisib is addedReport a problem
- Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBCRecruitingPhase 3Shanghai Jiao Tong University School of MedicineNCT07797218In every armBoth arms take it with docetaxel; pyrotinib is added firstWritten as PertuzumabReport a problem
- Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast CancerNot yet recruitingPhase 2Shengjing HospitalNCT07795424In every armPartner of new culmerciclib with letrozoleWritten as Pertuzumab (TQB2440)Report a problem
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingPhase 1/2DualityBio Inc.NCT05150691Partner of new trastuzumab pamirtecan in some armsWritten as Pertuzumab InjectionReport a problem
- Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding StudyRecruitingPhase 1/2Liu ShuNCT07739511In every armPartner of oral paclitaxel at rising dosesWritten as Paclitaxel oral solution plus Trastuzumab and PertuzumabReport a problem
- Culmerciclib in HR+/HER2+ Advanced Breast CancerRecruitingPhase 2Sun Yat-sen UniversityNCT07732491Anti-HER2 partner of new culmerciclibReport a problem
- Neoadjuvant SHR-A1811 and SHR-A1701 ± Pertuzumab for Potentially Immunotherapy-Sensitive GC or GEJ AdenocarcinomaNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07716111Partner of new SHR-A1811 and retlirafusp alfa in one armReport a problem
- Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07716046In every armBoth arms take it with trastuzumab; new fulvestaciclib is addedWritten as PertuzumabReport a problem
- A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid TumorRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT07140393Partner of new HRS-4508Written as HRS-4508+ Trastuzumab+ PertuzumabReport a problem
- Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast CancerRecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT07647263Part of THP; a switch to SHR-A1811 is testedReport a problem
- A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast CancerRecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07518173In every armPartner of new BL-M07D1; also in the comparatorWritten as PertuzumabReport a problem
- Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast CancerRecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT07616427In every armPartner of new fovinaciclib with an aromatase inhibitorWritten as Trastuzumab + PertuzumabReport a problem
- Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast CancerRecruitingPhase 2Sun Yat-sen UniversityNCT07610720In every armPartner of dalpiciclib maintenanceWritten as PertuzumabReport a problem
- Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast CancerRecruitingPhase 2University of WashingtonNCT04329065In every armGiven with chemotherapy; WOKVAC vaccine is addedWritten as PertuzumabReport a problem
- Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHPNot yet recruitingPhase 4The First Affiliated Hospital with Nanjing Medical UniversityNCT07589699Optional after trastuzumab rezetecan in adjuvant therapyReport a problem
Showing 20 of 83. See all 83 →
Beside supportive care · 14 — a supportive treatment or test is studied
- Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular ImagingNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT07527806In every armStandard; HER2-PET guides the change of treatmentWritten as PertuzumabReport a problem
- Correlation of Clinical Response to Pathologic Response in Patients With Early Breast CancerRecruitingPhase 2Baylor Breast Care CenterNCT05020860A standard regimen; response assessment is studiedWritten as PertuzumabReport a problem
- Aromatherapy in the Treatment of Early Breast CancerNot yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06435104Part of neoadjuvant therapy; aromatherapy is addedReport a problem
- Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast CancerRecruitingNot applicableFudan UniversityNCT04281641Part of TCHP; markers of response are studiedReport a problem
- Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast CancerTerminatedPhase 2Mayo ClinicNCT04249622Given as treatment; rifaximin is tested for its diarrhoeaReport a problem
- Supervised Physical Activity in Young Women With Early Breast Cancer During Neoadjuvant ChemotherpyActive, not recruitingNot applicableThe Greater Poland Cancer CentreNCT06190600Given to HER2-positive patients; interval training is addedReport a problem
- A Prospective Study of Breast Cancer Patients With Abnormal Strain ImagingStatus unknownPhase 2Northwestern UniversityNCT02993198Some patients take it; carvedilol is testedReport a problem
- Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer PatientsCompletedPhase 2Sandra SwainNCT02910219Patients take it; crofelemer is testedReport a problem
- Cardiac Safety Study in Patients With HER2 + Breast CancerCompletedPhase 2Medstar Health Research InstituteNCT01904903In every armHER2 therapy continues; heart medicines are testedWritten as PertuzumabReport a problem
- The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.TerminatedNot applicableInstitut Claudius RegaudNCT03619044Given with trastuzumab and a taxane; FES-PET is studiedReport a problem
- MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project ICompletedPhase 4AgendiaNCT01501487Standard neoadjuvant option; MammaPrint is the questionReport a problem
- Fasting on Newly Diagnosed Breast CancerTerminatedPhase 1/2Western Regional Medical CenterNCT02379585Given to HER2-positive patients; short-term fasting is testedWritten as PertuzumabReport a problem
- The Efficacy of Acupuncture in Treating Chemotherapy Side Effects in Breast Cancer PatientsTerminatedNot applicableOhioHealthNCT01996410Given with chemotherapy; acupuncture is studiedReport a problem
- Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease ProgressionCompletedPhase 2Genentech, Inc.NCT00943670In every armGiven with trastuzumab emtansine in some; heart rhythm studiedWritten as pertuzumabReport a problem
One option of several · 8 — a test or a strategy chooses among drugs
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT04802759One partner in an umbrella studyReport a problem
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingPhase 2Peking Union Medical CollegeNCT06145308One partner in molecular-typed salivary cohortsWritten as AR,AR antagonist ++ goserelin + pertuzumab + trastuzumabReport a problem
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingPhase 2Canadian Cancer Trials GroupNCT03297606One matched drug pair in a profiling trialWritten as Trastuzumab plus PertuzumabReport a problem
- Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast CancerRecruitingNot applicableFundacio Clinic BarcelonaNCT06446882One option in HER2DX-guided treatmentReport a problem
- A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCCRecruitingPhase 1/2Fudan UniversityNCT04215003Part of one subtype's regimen in a molecular platformReport a problem
- Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer PatientsRecruitingPhase 1/2Peking University People's HospitalNCT04750122Part of neoadjuvant therapy; drug screening guides chemotherapyReport a problem
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedPhase 1OHSU Knight Cancer InstituteNCT03878524In every armOne of many drugs in individualised combinationsWritten as PertuzumabReport a problem
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingPhase 2Fondazione per la Medicina PersonalizzataNCT04591431One option in tailored therapyWritten as PertuzumabReport a problem
Given beside what is tested · 1 — usual care or a partner of the new treatment
As the comparator · 33 — what is tested is compared with pertuzumab
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerRecruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT07043725The comparator with trastuzumab for new TQB2102Written as Trastuzumab injection and Pertuzumab Injection and Docetaxel Injection and Carboplatin InjectionReport a problem
- A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerRecruitingPhase 2Jazz PharmaceuticalsNCT07102381The comparator with trastuzumab and chemotherapy for zanidatamabWritten as PertuzumabReport a problem
- Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX29 Compared With HLX11Not yet recruitingPhase 1Shanghai Henlius BiotechNCT07776132The reference HLX11 for new HLX29Written as HLX11Report a problem
- Comparative Study of QL1209 and Perjeta® in Healthy Male ParticipantsNot yet recruitingPhase 1Qilu Pharmaceutical Co., Ltd.NCT07861139The reference Perjeta for biosimilar QL1209Report a problem
- SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete ResponseNot yet recruitingPhase 2Fudan UniversityNCT07856303The comparator with trastuzumab for SHR-A1811Written as PertuzumabReport a problem
- NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast CancerRecruitingPhase 2West German Study GroupNCT05704829The comparator with trastuzumab and chemotherapy for T-DXdReport a problem
- A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast CancerNot yet recruitingPhase 1Shanghai Henlius BiotechNCT07601620The reference Phesgo for biosimilar HLX319Report a problem
- A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast CancerNot yet recruitingPhase 2Shanghai JMT-Bio Inc.NCT07545044The comparator with trastuzumab for new JSKN003Written as PertuzumabReport a problem
- A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast CancerRecruitingPhase 3Shanghai JMT-Bio Inc.NCT07441460The comparator with trastuzumab for new KN026 after surgeryWritten as PertuzumabReport a problem
- Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 Compared With EU-Phesgo®Not yet recruitingPhase 1Shanghai Henlius BiotechNCT07495930The reference Phesgo for biosimilar HLX319Report a problem
- ctDNA in HER2+ EBC Neoadjuvant TreatmentRecruitingPhase 2Shanghai Jiao Tong University School of MedicineNCT07335081The comparator for pyrotinib-initiated treatmentWritten as pertuzumabReport a problem
- Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast CancerRecruitingPhase 2Karolinska University HospitalNCT05900206Part of standard treatment against T-DXd before surgeryWritten as PertuzumabReport a problem
- Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.Not yet recruitingPhase 2Henan Cancer HospitalNCT07136974Part of TCbHP against new TQB2102Written as Docetaxel + Carboplatin + Trastuzumab +PertuzumabReport a problem
- A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast CancerRecruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT07003074The comparator with docetaxel and trastuzumab for TQB2102Report a problem
- Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.RecruitingPhase 3Shanghai JMT-Bio Inc.NCT05838066The comparator with trastuzumab and docetaxel for new KN026Written as PertuzumabReport a problem
- A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular RelapseRecruitingPhase 3Prof. Wolfgang JanniNCT06643585One comparator option against T-DXdReport a problem
- T-DXd Versus THP for Medium-risk HER2-positive Early Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT06548178The comparator with docetaxel and trastuzumab for T-DXdReport a problem
- Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical TrialRecruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06278870The comparator with trastuzumab and a taxane for disitamab vedotinWritten as PertuzumabReport a problem
- Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast CancerRecruitingPhase 2Shengjing HospitalNCT05638594The comparator TCbHP for pyrotinib, dalpiciclib and letrozoleWritten as PertuzumabReport a problem
- Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast CancerNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT05430347The comparator for pyrotinib with TCbReport a problem
Showing 20 of 33. See all 33 →
Observed · 44 — patients on it are followed, or it is given outside a trial
- Clinical and Therapeutic Outcomes by Molecular Subtype in Breast CancerRecruitingFundación Santa Fe de BogotaNCT07856225One therapy recorded by molecular subtypeReport a problem
- Emotional Distress in Patients With Metastatic Breast Cancer in First Line of TherapyRecruitingEuropean Institute of OncologyNCT06994377One treatment recorded in a distress studyReport a problem
- Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast CancerRecruitingCentre Paul StraussNCT04638725One treatment group in a genetic resistance studyReport a problem
- Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic DiseaseRecruitingSociété Algérienne de Formation et Recherche en OncologieNCT07542496Real-world use of a pertuzumab biosimilarReport a problem
- A Real-World Study on the Impact of Different Adjuvant Treatment Regimens on Prognosis in Non-pCR Patients With HER2-Positive Breast Cancer After Neoadjuvant TherapyNot yet recruitingHebei Medical University Fourth HospitalNCT07540520Adjuvant use against T-DM1, observedReport a problem
- Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast CancerNot yet recruitingPeking University Cancer Hospital & InstituteNCT07470203With pyrotinib and trastuzumab as maintenance in practiceWritten as PertuzumabReport a problem
- Efficacy of Neoadjuvant Subcutaneous Trastuzumab-Pertuzumab in Algerian Women With Locally Advanced HER2 Positive Breast CancerRecruitingBlida 1 UniversityNCT07166185Neoadjuvant subcutaneous use in Algerian womenReport a problem
- Concomitant Radiotherapy and New Drugs in Metastatic Breast CancerRecruitingFondazione Policlinico Universitario Campus Bio-MedicoNCT07021911One treatment group in a radiotherapy studyReport a problem
- Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast CancerRecruitingShu WangNCT06722612Adjuvant use in high-risk node-negative patientsReport a problem
- Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive PatientsRecruitingShu WangNCT06722599Four cycles with a taxane, observedReport a problem
- Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target TherapyRecruitingShu WangNCT06711068Adjuvant use in node-negative patientsReport a problem
- De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive PatientsRecruitingShu WangNCT06700369Neoadjuvant use; the chemotherapy differsReport a problem
- Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant TherapyRecruitingShu WangNCT06693037Adjuvant use against T-DM1, observedReport a problem
- Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast CancerRecruitingInstitut Català d'OncologiaNCT05912062Early transcriptional predictors of responseWritten as Pertuzumab (neoadjuvant)Report a problem
- Neoadjuvant Treatment of Breast CancerNot yet recruitingNational Institute of Oncology, HungaryNCT05131893One treatment recorded before breast surgeryWritten as pertuzumabReport a problem
- Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical StudyNot yet recruitingFudan UniversityNCT04831528One later option after cetuximab failureReport a problem
- KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors IIActive, not recruitingSeoul National University Bundang HospitalNCT05525858One matched drug pair in a molecular profiling programmeWritten as Trastuzumab + PertuzumabReport a problem
- First-Line Dual Versus Single HER2-Targeted Therapy With Docetaxel for Advanced HER2-Positive Breast CancerCompletedXin LiNCT07829900Dual against single HER2 therapy in practiceWritten as PertuzumabReport a problem
- A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin AmericaCompletedHoffmann-La RocheNCT04158258One treatment recorded in Latin American breast cancerWritten as PertuzumabReport a problem
- Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 TreatmentActive, not recruitingNagoya City UniversityNCT06663787ctDNA in patients continuing or stopping HER2 therapyReport a problem
Showing 20 of 44. See all 44 →
As a tool · 4 — an imaging tracer or a test of drug response
- Testing a New Imaging Agent to Identify CancerActive, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT04692831Labelled with zirconium-89 for PET imagingReport a problem
- Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?CompletedNot applicableMemorial Sloan Kettering Cancer CenterNCT02286843Labelled with zirconium-89 for PET imagingReport a problem
- Imaging With a New Agent That Finds a Cancer Protein Called HER2CompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT03109977Labelled with zirconium-89 for PET imagingReport a problem
- Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)TerminatedPhase 1Ontario Clinical Oncology Group (OCOG)NCT01805908Labelled with indium-111 for imagingReport a problem
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted1
- Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or BevacizumabNov 12, 2026NCT02436993
Newly registered1
Codes
What other systems call pertuzumab · ClinicalTrials.gg INT004642
- MeSH (NLM) C485206pertuzumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) K16AIQ8CTMPERTUZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1298944Confirmed FDA, Wikidata
- Wikidata Q1998021pertuzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C38692PertuzumabOne source FDA
- DrugBank DB06366One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C485206 | pertuzumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | K16AIQ8CTM | PERTUZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1298944 | — | Confirmed FDA, Wikidata |
| Wikidata | Q1998021 | pertuzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C38692 | Pertuzumab | One source FDA |
| DrugBank | DB06366 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.